Abstract:Amyotrophic lateral sclerosis (ALS) is an intractable disease that causes respiratory failure leading to mortality. The main locus of ALS is motor neurons. The success of antisense oligonucleotide (ASO) therapy in spinal muscular atrophy (SMA), a motor neuron disease, has triggered a paradigm shift in developing ALS therapies. The causative genes of ALS and disease-modifying genes, including those of sporadic ALS, have been identified one after another. Thus, the freedom of target choice for gene therapy has expanded by ASO strategy, leading to new avenues for therapeutic development. Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO for ALS. Improving protocols and devising early interventions for the disease are vital. In this review, we updated the knowledge of causative genes in ALS. We summarized the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma (FUS), and transacting response DNA-binding protein. The frequency of the C9ORF72 mutation is low in Japan, unlike in Europe and the United States, while SOD1 and FUS are more common, indicating that the target mutations for gene therapy vary by ethnicity. A genome-wide association study has revealed disease-modifying genes, which could be the novel target of gene therapy. The current status and prospects of gene therapy development were discussed, including ethical issues. Furthermore, we discussed the potential of axonal pathology as new therapeutic targets of ALS from the perspective of early intervention, including intra-axonal transcription factors, neuromuscular junction disconnection, dysregulated local translation, abnormal protein degradation, mitochondrial pathology, impaired axonal transport, aberrant cytoskeleton, and axon branching. We simultaneously discuss important pathological states of cell bodies: persistent stress granules, disrupted nucleocytoplasmic transport, and cryptic splicing. The development of gene therapy based on the elucidation of disease-modifying genes and early intervention in molecular pathology is expected to become an important therapeutic strategy in ALS.

The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

Novel therapeutic targets for amyotrophic lateral sclerosis: ribonucleoproteins and cellular autonomy

Prion-Like Mechanisms in Parkinson’s Disease

Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS

Molecular Chaperones' Potential against Defective Proteostasis of Amyotrophic Lateral Sclerosis

Targeting Prion-Like Protein Spreading in Neurodegenerative Diseases

Autophagy and Its Comprehensive Impact on ALS

Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases

Targeting Protein Aggregation in ALS

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies

New implications for prion diseases therapy and prophylaxis

Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights

Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy

Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors

Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis

Chemical chaperones targeted to the endoplasmic reticulum (ER) and lysosome prevented neurodegeneration in a C9orf72 repeat expansion drosophila amyotrophic lateral sclerosis (ALS) model

A combinatorial approach to ALS therapies in the PrP.TDP43-315 model of ALS; complications and tribulations

A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?

Prion-like Mechanisms in Alzheimer's Disease.